Back to News
Dec 1, 2025 4:00 PM

Zepbound Just Got Cheaper: Lilly Cuts Prices On LillyDirect To Broaden Access

Eli Lilly and Co. (NYSE:LLY) on Monday announced that Zepbound (tirzepatide) single-dose vials will now be available at lower prices on LillyDirect, the company's digital healthcare platform. Zepbound is a prescription drug for weight loss.

The update builds on Lilly's ongoing efforts to lower out-of-pocket costs in the United States.

By lowering the prices of Zepbound single-dose vials, Lilly is offering patients greater access and flexibility in their treatment.

With a valid prescription, patients can access the starting dose of Zepbound single-dose vial (2.5 mg) for as low as $299 per month from $349.

The 5 mg dose ...